Skip to main content

Advertisement

Table 1 Clinical patient characteristics

From: The CD31 molecule: a possible neuroprotective agent in acute ischemic stroke?

Characteristic n = 86
Age (years): median, range 72, 21–92
Sex
 Female 40 (47%)
Occlusion site
 MCA 50 (58%)
 ICA including carotid-T 22 (26%)
 Combined ICA and MCA/ACA 13 (15%)
 ACA 1 (1%)
Baseline NIHSS (range, median), n = 81 (94.2%) 15, 2–27
IV rtPA 57 (66%)
Time symptom onset to reperfusion (min): median, range, n = 70 (81.4%) 280 (0–495)
mRS (90 days), n = 41 (47.7%)
 0–2 17 (39.1%)
  > 2 24 (60.9%)
Stroke etiology (TOAST), n = 85
 1 = arterioembolic 16 (18.8%)
 2 = cardioembolic 40 (47.1%)
 4 = other determined cause 9 (10.6%)
 5 = cryptogenic 20 (23.5%)
  1. Basic demographic and clinical patient characteristics (MCA middle cerebral artery, ICA internal carotid artery, ACA anterior cerebral artery, IV rtPA intravenous recombinant tissue plasminogen activator)